HK1155170A1 - Pyridine compounds - Google Patents
Pyridine compoundsInfo
- Publication number
- HK1155170A1 HK1155170A1 HK11109503.8A HK11109503A HK1155170A1 HK 1155170 A1 HK1155170 A1 HK 1155170A1 HK 11109503 A HK11109503 A HK 11109503A HK 1155170 A1 HK1155170 A1 HK 1155170A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- pyridine compounds
- pyridine
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7305508P | 2008-06-17 | 2008-06-17 | |
| PCT/GB2009/050675 WO2009153589A1 (en) | 2008-06-17 | 2009-06-15 | Pyridine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1155170A1 true HK1155170A1 (en) | 2012-05-11 |
Family
ID=40896110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK11109503.8A HK1155170A1 (en) | 2008-06-17 | 2011-09-08 | Pyridine compounds |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8569298B2 (ja) |
| EP (1) | EP2303861B1 (ja) |
| JP (1) | JP5551689B2 (ja) |
| KR (1) | KR101695501B1 (ja) |
| CN (1) | CN102124000B (ja) |
| AU (1) | AU2009261764B2 (ja) |
| BR (1) | BRPI0914927B8 (ja) |
| CA (1) | CA2726508C (ja) |
| CR (1) | CR11854A (ja) |
| DO (1) | DOP2010000390A (ja) |
| EA (1) | EA020807B1 (ja) |
| EC (1) | ECSP10010695A (ja) |
| ES (1) | ES2472323T3 (ja) |
| HK (1) | HK1155170A1 (ja) |
| IL (1) | IL209727A0 (ja) |
| MX (1) | MX2010014057A (ja) |
| WO (1) | WO2009153589A1 (ja) |
| ZA (1) | ZA201100388B (ja) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140155410A1 (en) * | 2008-10-27 | 2014-06-05 | Glaxosmithkline Llc | Pyrazolylaminopyridines as inhibitors of fak |
| JO3067B1 (ar) | 2008-10-27 | 2017-03-15 | Glaxosmithkline Llc | بيرميدينات بيرازولو امينو كمثبطات ل fak |
| WO2010068947A2 (en) * | 2008-12-12 | 2010-06-17 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Nuclear export inhibitors of topoisomerase ii alpha |
| US8952034B2 (en) | 2009-07-27 | 2015-02-10 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| RU2528386C2 (ru) | 2010-05-21 | 2014-09-20 | Кемилиа Аб | Новые производные пиримидина |
| AU2011276552B2 (en) | 2010-06-29 | 2015-09-03 | Verastem, Inc. | Oral formulation of kinase inhibitors |
| NZ604801A (en) | 2010-06-30 | 2015-03-27 | Verastem Inc | Synthesis and use of focal adhesion kinase inhibitors |
| WO2012003392A1 (en) | 2010-07-02 | 2012-01-05 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| US20120244141A1 (en) | 2010-09-28 | 2012-09-27 | Boehringer Ingelheim International Gmbh | Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors |
| KR20140011322A (ko) * | 2011-01-26 | 2014-01-28 | 글락소스미스클라인 인털렉츄얼 프로퍼티 리미티드 | 조합물 |
| WO2012110774A1 (en) | 2011-02-17 | 2012-08-23 | Cancer Therapeutics Crc Pty Limited | Selective fak inhibitors |
| AU2012216893B2 (en) | 2011-02-17 | 2016-08-11 | Cancer Therapeutics Crc Pty Limited | FAK inhibitors |
| CA2830129C (en) | 2011-03-24 | 2016-07-19 | Chemilia Ab | Novel pyrimidine derivatives |
| EP2707361B1 (en) | 2011-05-10 | 2017-08-23 | Gilead Sciences, Inc. | Fused heterocyclic compounds as sodium channel modulators |
| TWI549944B (zh) | 2011-07-01 | 2016-09-21 | 吉李德科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
| NO3175985T3 (ja) | 2011-07-01 | 2018-04-28 | ||
| TW201341367A (zh) | 2012-03-16 | 2013-10-16 | Axikin Pharmaceuticals Inc | ３，５－二胺基吡唑激酶抑制劑 |
| NZ631142A (en) | 2013-09-18 | 2016-03-31 | Axikin Pharmaceuticals Inc | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors |
| SG11201609386YA (en) * | 2014-06-17 | 2017-01-27 | Pfizer | Substituted dihydroisoquinolinone compounds |
| US9442005B2 (en) | 2014-07-30 | 2016-09-13 | Corning Optical Communications LLC | Non-contact methods of measuring insertion loss in optical fiber connectors |
| CN107250116B (zh) | 2014-12-23 | 2020-10-27 | 艾士盟医疗公司 | 3,5-二氨基吡唑激酶抑制剂 |
| GB201510010D0 (en) | 2015-06-09 | 2015-07-22 | King S College London | PDD and BPD compounds |
| AU2016286091B2 (en) | 2015-06-29 | 2021-02-04 | Verastem, Inc. | Therapeutic compositions, combinations, and methods of use |
| GB201514928D0 (en) | 2015-08-21 | 2015-10-07 | King S College London | PDD compounds |
| US20180339985A1 (en) | 2015-08-21 | 2018-11-29 | Femtogenix Limited | Pdd compounds |
| JP7444780B2 (ja) | 2018-02-28 | 2024-03-06 | ビーエーエスエフ ソシエタス・ヨーロピア | 硝化阻害剤としてのｎ－官能化アルコキシピラゾール化合物の使用 |
| CA3089381A1 (en) | 2018-02-28 | 2019-09-06 | Basf Se | Use of pyrazole propargyl ethers as nitrification inhibitors |
| CN112218658A (zh) | 2018-03-12 | 2021-01-12 | 国家健康科学研究所 | 热量限制模拟物用于增强癌症治疗的化学免疫疗法的用途 |
| CN108912095B (zh) * | 2018-08-09 | 2019-08-20 | 广州安岩仁医药科技有限公司 | 苯并咪唑类化合物及其制备方法和应用 |
| CN114793434A (zh) * | 2019-10-18 | 2022-07-26 | 加利福尼亚大学董事会 | 作为用于治疗病原性血管病症的药剂的3-苯基磺酰基-喹啉衍生物 |
| BR112023024208A2 (pt) | 2021-05-21 | 2024-01-30 | Basf Se | Uso de um composto, composição, mistura agroquímica e métodos para reduzir nitrificação e para tratar um fertilizante |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| DE10336184A1 (de) | 2003-08-07 | 2005-02-24 | Bayer Materialscience Ag | Neue Katalysatoren für die selektive Isocyanatdimerisierung |
| CA2533320A1 (en) * | 2003-08-15 | 2006-02-24 | Novartis Ag | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
| BRPI0512342A (pt) | 2004-06-21 | 2008-03-04 | Pharmacia & Upjohn Co Llc | métodos para aumento ósseo |
| GB0419161D0 (en) * | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
| GB0419160D0 (en) | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
| EP1841760B1 (en) | 2004-12-30 | 2011-08-10 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
| CA2632149C (en) * | 2005-12-01 | 2011-11-15 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
| UA89123C2 (ru) | 2005-12-21 | 2009-12-25 | Пфайзер Продактс Инк. | Производные пиримидина для лечения абнормального роста клеток |
| JP5208123B2 (ja) | 2006-12-08 | 2013-06-12 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
| CA2681015C (en) * | 2007-03-16 | 2016-06-21 | The Scripps Research Institute | Inhibitors of focal adhesion kinase |
| US20100190777A1 (en) * | 2007-07-17 | 2010-07-29 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| EP2249650A4 (en) * | 2008-02-19 | 2012-01-11 | Glaxosmithkline Llc | ANILINOPYRIDINE AS A FAK HEMMER |
-
2009
- 2009-06-15 JP JP2011514125A patent/JP5551689B2/ja active Active
- 2009-06-15 MX MX2010014057A patent/MX2010014057A/es active IP Right Grant
- 2009-06-15 BR BRPI0914927A patent/BRPI0914927B8/pt active IP Right Grant
- 2009-06-15 US US12/999,025 patent/US8569298B2/en active Active
- 2009-06-15 EP EP09766150.8A patent/EP2303861B1/en active Active
- 2009-06-15 CA CA2726508A patent/CA2726508C/en active Active
- 2009-06-15 WO PCT/GB2009/050675 patent/WO2009153589A1/en active Application Filing
- 2009-06-15 CN CN200980132565.2A patent/CN102124000B/zh active Active
- 2009-06-15 AU AU2009261764A patent/AU2009261764B2/en active Active
- 2009-06-15 EA EA201100032A patent/EA020807B1/ru not_active IP Right Cessation
- 2009-06-15 KR KR1020117001022A patent/KR101695501B1/ko active IP Right Grant
- 2009-06-15 ES ES09766150.8T patent/ES2472323T3/es active Active
-
2010
- 2010-12-02 IL IL209727A patent/IL209727A0/en unknown
- 2010-12-17 DO DO2010000390A patent/DOP2010000390A/es unknown
- 2010-12-17 EC EC2010010695A patent/ECSP10010695A/es unknown
- 2010-12-17 CR CR11854A patent/CR11854A/es not_active Application Discontinuation
-
2011
- 2011-01-14 ZA ZA2011/00388A patent/ZA201100388B/en unknown
- 2011-09-08 HK HK11109503.8A patent/HK1155170A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102124000B (zh) | 2014-09-17 |
| BRPI0914927B1 (pt) | 2020-10-06 |
| KR20110023884A (ko) | 2011-03-08 |
| AU2009261764A1 (en) | 2009-12-23 |
| MX2010014057A (es) | 2011-03-21 |
| BRPI0914927A2 (pt) | 2017-06-20 |
| JP5551689B2 (ja) | 2014-07-16 |
| CA2726508A1 (en) | 2009-12-23 |
| ES2472323T3 (es) | 2014-06-30 |
| WO2009153589A1 (en) | 2009-12-23 |
| KR101695501B1 (ko) | 2017-01-11 |
| AU2009261764B2 (en) | 2013-01-10 |
| US8569298B2 (en) | 2013-10-29 |
| EP2303861B1 (en) | 2014-04-23 |
| EA201100032A1 (ru) | 2012-01-30 |
| BRPI0914927B8 (pt) | 2021-05-25 |
| EP2303861A1 (en) | 2011-04-06 |
| JP2011524411A (ja) | 2011-09-01 |
| IL209727A0 (en) | 2011-02-28 |
| ECSP10010695A (es) | 2011-01-31 |
| CN102124000A (zh) | 2011-07-13 |
| DOP2010000390A (es) | 2011-01-15 |
| EA020807B1 (ru) | 2015-01-30 |
| CR11854A (es) | 2011-02-25 |
| US20110166139A1 (en) | 2011-07-07 |
| ZA201100388B (en) | 2011-10-26 |
| CA2726508C (en) | 2016-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1155170A1 (en) | Pyridine compounds | |
| GB0807862D0 (en) | Compounds | |
| GB0800035D0 (en) | Compounds | |
| IL206276A0 (en) | Pyridine derivatives | |
| GB0804702D0 (en) | Compounds | |
| GB0809776D0 (en) | Compounds | |
| IL205666A0 (en) | Pyridine compounds | |
| GB0807103D0 (en) | Compounds | |
| EP2301922A4 (en) | pyridone | |
| GB0807910D0 (en) | Compounds | |
| GB0801220D0 (en) | Compounds | |
| GB0801265D0 (en) | Compounds | |
| GB0806449D0 (en) | Compounds | |
| GB0805311D0 (en) | Compounds | |
| GB0808123D0 (en) | Compounds | |
| GB0808119D0 (en) | Compounds | |
| GB0807911D0 (en) | Compounds | |
| GB0808669D0 (en) | Compounds | |
| GB0809771D0 (en) | Compounds | |
| GB0807415D0 (en) | Compounds | |
| GB0810118D0 (en) | Compounds | |
| GB0807047D0 (en) | Compounds | |
| GB0803496D0 (en) | Compounds | |
| GB0806448D0 (en) | Compounds | |
| GB0806083D0 (en) | Compounds |